drugset
Drugs / SW-BIC-213
last change Feb 2024 re-read 2 minutes ago

SW-BIC-213

Messenger RNA (mRNA)

Investigated by
Stemirna Therapeutics

Trials 2 · a red edge is where a trial was stopped

today NCT05686161 · Ph 3 NCT05580159 · Ph 3
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05686161 Oct → Dec 2022 — Stemirna Therapeutics Unknown No outcome recorded
Phase 3 NCT05580159 Oct 2022 → May 2023 — Stemirna Therapeutics Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT05911087 Comparator Jun → Jul 2023 — Stemirna Therapeutics Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as SW-BIC-213 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911087 ↗
2

NCT05686161 ↗

NCT05580159 ↗
Modality Messenger RNA (mRNA) “The mRNA vaccine has demonstrated significant effectiveness in protecting against SARS-CoV-2 during the pandemic” PMID 38169790 ↗ Dec 2023
Route Intramuscular “Route of Administration: injection Intramuscular” NCT05580159 ↗